
first trial over the once-blockbuster painkiller Vioxx " /> Vioxx on Tuesday cleared the drug's maker in the 2003 deadly heart attack of a 52-year... court jury deliberated over two days before siding with Merck & ...

about the cardiovascular risks of Vioxx and played them down long before it voluntarily recalled the drug in September 2004. Merck is fighting the class action, claiming it did nothing wrong. The trial continues.

forms of scientific fraud. One study alleges that Merck gave the Food and Drug Administration an incomplete accounting of deaths in a clinical trial of Vioxx in people with mild dementia. Federal regulators eventua...

nice scoop by Ed Silverman about the Vioxx liability. The thrust is that Merck should have told participants in a clinical trial that Vioxx should cause heart attacks, but that it didn't. How this affects liability...

lawsuits, the vast majority of such cases. Merck won about two-thirds of the Vioxx personal injury lawsuits that went to trial. Merck shares fell 51 cents, or 1.4 percent, to $35.43 Tuesday, a day when the broader...

article had been paid to provide expertise for plaintiffs in Vioxx lawsuits. The Merck letter says the Advantage trial was legitimate and designed to answer previously unanswered questions about the use of Vioxx. ...

of heart attack and stroke in patients taking it for more than 18 months. Merck has won most of the Vioxx cases that have since gone to trial and gained leverage in negotiating the settlement that many called favora...

Reuters) - Merck & Co. scored its second swift victory this week in a Vioxx " /> Vioxx product liability trial when an Alabama jury found on Friday it did not hide health risks associated with its withdrawn arthriti...

against Merck in a Vioxx case. The widow of a 59-year-old triathelete still takes nothing. In May 2008 the 14th Texas Court of Appeals ruled that... caused Bob Ernst's heart problem and death. The 2005 trial was ...

risk. Merck introduced Vioxx to the market in May 1999 and the drug quickly became a commercial success, with sales reaching $2 billion annually... in an effort to provide a blueprint for use of clinical trial data. ...